Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Deferred Taxes: 2020-2021

Historic Deferred Taxes for Insight Molecular Diagnostics (IMDX) over the last 1 years, with Dec 2021 value amounting to $97,000.

  • Insight Molecular Diagnostics' Deferred Taxes rose 161.01% to $97,000 in Q4 2021 from the same period last year, while for Dec 2021 it was -$9.4 million, marking a year-over-year change of. This contributed to the annual value of -$9.3 million for FY2021, which is 638.52% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Deferred Taxes of $97,000 as of Q4 2021, which was up 105.41% from -$1.8 million recorded in Q2 2021.
  • Insight Molecular Diagnostics' 5-year Deferred Taxes high stood at $97,000 for Q4 2021, and its period low was -$7.6 million during Q1 2021.
  • Over the past 2 years, Insight Molecular Diagnostics' median Deferred Taxes value was -$1.1 million (recorded in 2020), while the average stood at -$2.1 million.
  • Over the last 5 years, Insight Molecular Diagnostics' Deferred Taxes had its largest YoY gain of 161.01% in 2021, and its largest YoY loss of 590.78% in 2021.
  • Insight Molecular Diagnostics' Deferred Taxes (Quarterly) stood at -$159,000 in 2020, then skyrocketed by 161.01% to $97,000 in 2021.
  • Its last three reported values are $97,000 in Q4 2021, -$1.8 million for Q2 2021, and -$7.6 million during Q1 2021.